Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

CVS Health : Expanding Access to Naloxone Saves Lives

share with twitter share with LinkedIn share with facebook
share via e-mail
06/12/2017 | 12:28pm CEST

Release date- 09062017 - CVS Health - Expanding Access to Naloxone Saves Lives.

According to the Centers for Disease Control and Prevention, more than 50,000 people died from drug overdoses in the U.S. in 2015.1 More than 60 percent involved an opioid.2

We know that Americans from all walks of life are finding that prescription drug abuse is hitting closer and closer to home; nearly one in three Americans report that they have been personally affected, according to a recent survey conducted by CVS Health.

While abuse-prevention education and outreach programs are vital for curbing drug misuse and abuse, one strategy that can help communities address overdoses in the moment is ensuring access to the life-saving drug naloxone.

What is Naloxone?

Naloxone, also known by the brand name Narcan, is a lifesaving drug that blocks opioid receptor sites to reverse the effects of an overdose.3 Over the past two years CVS Health has worked to expand access to naloxone without individual prescriptions in 41 states, most recently to CVS Pharmacy patients in Arizona.

Increasing Access to Naloxone Saves Lives

Many states have recently passed Naloxone Access Laws (NALs) that widen access to naloxone by providing specific statutory protections for nonmedical professionals to possess and administer naloxone without a prescription. This enables any person without a prescription to have naloxone and to give it to a person showing signs of an opioid overdose without having to fear legal repercussions.4

According to the National Bureau of Economic Research (NBER),5 states that have adopted NALs have seen a nine to 11 percent reduction in opioid-related deaths. This research underscores the importance of increasing access to naloxone as part of a larger strategy to address the impact of prescription drug abuse.

Community Leaders Amplify Naloxone's Value

During an event hosted by CVS Health, Arizona State Attorney General Mark Brnovich and State Representative Heather Carter joined CVS Health in announcing that naloxone would be available at all Arizona CVS Pharmacy locations without a prescription. Their remarks echoed the importance of naloxone in addressing prescription drug abuse and opioid abuse more broadly.

'The opioid epidemic is an urgent public health crisis facing Arizona and the entire country,' said Attorney General Brnovich. 'We want to ensure that Arizona families who have loved ones struggling with addiction have access to naloxone because it saves lives.'

Representative Carter, a sponsor of the naloxone access legislation signed into law last year, added, 'The main purpose behind the legislation I sponsored was to get this medication in the hands of a person who may have an opportunity to save a life.'

Our Ongoing Work

Opioid abuse is an epidemic that does not discriminate, and it continues to be an area of great concern and focus for CVS Health. There is no single cause to the problem, and the solution will require a multipronged effort including pharmacy, physicians, the pharmaceutical industry and government.

In addition to expanding access to naloxone, CVS Health is working to help communities address prescription drug abuse through education, outreach and safe medication disposal:

CVS Health's Medication Disposal for Safer Communities Program has donated more than 750 collection units to law enforcement partners across the country, allowing for the safe disposal of more than 80 metric tons of unwanted medication. This program offers an online search tool through which anyone can find a drop box location near them.

Pharmacists volunteering through the company's Pharmacists Teach program have helped educate more than 250,000 students about the dangers of prescription drug abuse.

For more information about our efforts in the fight against opioid abuse, visit our Prescription Drug Abuse information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH
08/23 CVS HEALTH : 's Accordant Earns NCQA Disease Management Accreditation for 18 Con..
08/21 CVS HEALTH CORP (NYSE : CVS) Study Reveals 66% of Americans Believe That Flu Sho..
08/19 CVS HEALTH : Laguna City Council to consider CVS' appeal to move into Laguna Dru..
08/19 INSIDER TRADING ACTIVITY CVS HEALTH : CVS) – Director Sold 2,500 shares o..
08/18 CVS HEALTH : SMART Clinic heads into its second year
08/18 UNITEDHEALTH : Corporate News Blog - UnitedHealth Group Announces New Leadership..
08/17 CVS PHARMACY : Earns URAC Reaccreditation in Community Pharmacy
08/17 CONSIDER YOUR PURPOSE : PA and PharmD Students Receive Short White Coats
08/16 CVS HEALTH : Prom night at YMCA Camp Oakes
08/16 CVS HEALTH : Survey Reveals Two in Three Americans who plan to get a Flu Shot Be..
More news
News from SeekingAlpha
08/22 5 Cheapest Funds For Dividend Investors
08/21 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q2 2017 Upda..
08/18 CVS Health Corporation 2017 Q2 - Results - Earnings Call Slides
08/18 This Bottoming Healthcare Stock Just Narrowed Its Guidance
08/17 TARGET REPORTS Q2 : Updating My Bullish Comments From Last Month
Financials ($)
Sales 2017 184 098 M
EBIT 2017 10 053 M
Net income 2017 5 304 M
Debt 2017 24 744 M
Yield 2017 2,54%
P/E ratio 2017 15,44
P/E ratio 2018 13,20
EV / Sales 2017 0,56x
EV / Sales 2018 0,54x
Capitalization 79 048 M
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 86,6 $
Spread / Average Target 11%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-1.61%79 048